Ian Riddock, MD
Cardiovascular Disease · Bend, ORNPI 1669582870
Payments from drug & device makers
Across 303 payments — averaging $656.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$113K
- Amgen$39K
- Boehringer Ingelheim$14K
- Amarin Pharma, Inc.$11K
- Regeneron Healthcare Solutions, Inc.$10K
- Sanofi-aventis U.S. LLC$5K
- plus $7K from 26 others
What the payments were for
- Consulting fees$3,4684%
- Speaking & faculty fees$58,20272%
- Travel & lodging$8,73211%
- Food & beverage$10,25613%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 41 | $113,185 |
| Amgen | 73 | $38,557 |
| Boehringer Ingelheim | 24 | $13,875 |
| Amarin Pharma, Inc. | 20 | $11,483 |
| Regeneron Healthcare Solutions, Inc. | 25 | $9,728 |
| Sanofi-aventis U.S. LLC | 8 | $4,962 |
| Boston Scientific | 23 | $2,265 |
| Lilly USA, LLC | 3 | $1,500 |
| Abbott | 20 | $684 |
| Novo Nordisk | 9 | $556 |
| Regeneron | 6 | $449 |
| Esperion Therapeutics, Inc. | 4 | $246 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $198 |
| Medtronic(2 entities) | 10 | $160 |
| Biotronik Inc. | 2 | $153 |
| Abiomed | 3 | $137 |
| Irhythm Technologies, Inc. | 5 | $122 |
| Ionis Pharmaceuticals, Inc. | 1 | $107 |
| Pfizer | 2 | $107 |
| Atricure, Inc. | 1 | $104 |
| AstraZeneca | 4 | $96 |
| Portola Pharmaceuticals, LLC | 1 | $91 |
| Lexicon Pharmaceuticals, Inc. | 2 | $61 |
| Impulse Dynamics (USA) Inc. | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $43 |
| Merck | 2 | $33 |
| Nevro Corp. | 1 | $19 |
| Verona Pharma, Inc. | 1 | $18 |
| Kestra Medical Technology Services, Inc. | 1 | $17 |
| Braemar Manufacturing, LLC | 1 | $17 |
| Heartflow, Inc. | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$29,909
- JARDIANCE$15,082
- PRALUENT$11,444
- Vascepa$10,952
- DISEASE STATE$2,650
- INGEVITY$712
- S-ICD System Magnet$675
- LEQVIO$486
- EVKEEZA$146
- Wegovy$131
- NEXLETOL$120
- Confirm Rx$115
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$104
- ATRICLIP LAA EXCLUSION SYSTEM$104
- AVEIR$103
How this compares
$199,044 in reported general payments places this provider in the 95th percentile of 198 cardiovascular disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 210 | $274,817 |
| JardianceEmpagliflozin | 159 | $239,564 |
| Repatha SureclickEvolocumab | 122 | $126,188 |
| XareltoRivaroxaban | 49 | $62,542 |
| EntrestoSacubitril/Valsartan | 38 | $58,873 |
| OzempicSemaglutide | 40 | $54,760 |
| Ezetimibe | 810 | $35,347 |
| FarxigaDapagliflozin Propanediol | 24 | $29,894 |
| VascepaIcosapent Ethyl | 32 | $21,895 |
| Rosuvastatin Calcium | 543 | $13,834 |
| Praluent PenAlirocumab | 21 | $13,454 |
| Icosapent Ethyl | 29 | $6,526 |
| Atorvastatin Calcium | 233 | $3,874 |
| Metoprolol Succinate | 229 | $3,317 |
| Flecainide Acetate | 47 | $2,743 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $107 | $274,817210 claims |
| Boehringer IngelheimJardiance | $13,875 | $239,564159 claims |
| NovartisEntresto | $113,185 | $58,87338 claims |
| Novo NordiskOzempic | $556 | $54,76040 claims |
| AstraZenecaFarxiga | $96 | $29,89424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 198 cardiovascular disease providers in Oregon.
Other cardiovascular disease in Bend
- Firas ZahrPortland$7.7M
- Ahmad MasriPortland$2.6M
- Scott ChadderdonPortland$1.6M
- Tyler GluckmanPortland$755K
- Stephen HeitnerPortland$434K
- Kathy GreweHood River$376K
- Matthew TrojanSpringfield$255K
- Maros FerencikPortland$239K
- Ashwat DhillonCorvallis$156K
- Abigail KhanPortland$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.